Validating Antibodies for Quantitative Western Blot Measurements with Microwestern Array
Preprint
Abstract
Western blotting is often considered a semi-quantitative or even qualitative assay for assessing changes in protein or protein post-translational modification levels. Fluorescence-based measurement enables acquisition of quantitative data in principal, but requires determining the linear range of detection for each antibody—a labor-intensive task. Here, we describe the use of a high-throughput western blotting technique called microwestern array to more rapidly evaluate suitable conditions for quantitative western blotting with particular antibodies. We can evaluate up to 192 antibody/dilution/replicate combinations on a single standard size gel with a seven-point, two-fold lysate dilution series (~100-fold range). Pilot experiments demonstrate a surprisingly high proportion of investigated antibodies (17/22) are suitable for quantitative use, and that lack of validity might often be a consequence of lysate composition rather than antibody quality. Linear range for all validated antibodies is at least 8-fold, and in some cases nearly two orders of magnitude. That range could be greater as the presented tests did not find a limit for many antibodies. We find that phospho-specific and total antibodies do not have discernable trend differences in linear range or limit of detection, but total antibodies generally required higher working concentrations, suggesting phospho-specific antibodies may be generally higher affinity. Importantly, we demonstrate that results from microwestern analyses scale to normal “macro” western for a subset of antibodies. These data indicate that with initial validation, many antibodies can be readily used quantitatively in a reproducible manner. Antibody validation data and standard operating procedures are available online ( www.birtwistlelab.com/protocols and www.dtoxs.org ).Keywords
All Related Versions
- Published version: Scientific Reports, 8 (1), 11329.
This publication has 30 references indexed in Scilit:
- Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarateeLife, 2017
- Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemiaeLife, 2017
- The challenges of replicationeLife, 2017
- Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorseLife, 2017
- Replication Study: Melanoma genome sequencing reveals frequent PREX2 mutationseLife, 2017
- Replication Study: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugseLife, 2017
- Replication Study: Discovery and preclinical validation of drug indications using compendia of public gene expression dataeLife, 2017
- Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-MyceLife, 2017
- Drug response consistency in CCLE and CGPNature, 2016
- Inconsistency in large pharmacogenomic studiesNature, 2013